Glaxo UK to outsource aerosols to Cipla?

Published on Fri, Jul 06, 2007 at 12:14 |  Source : Moneycontrol.com

Updated at Fri, Jul 06, 2007 at 22:40  

39295 Investors following Cipla. Share this News with them.
0
0
Share on Tumblr

Excerpts from Markets Midday on CNBC-TV18 Watch the full show ยป

RELATED NEWS

ALSO READ

Other Stocks in this news

GlaxoSmithKline Pharmaceuticals |

GlaxoSmithkline Pharma may strike a sourcing deal with Cipla for inhalation devices. It is learnt that the two companies are holding discussions that may benefit both, reports CNBC-TV18.

It looks like tradtional rivals GlaxoSmithkline Pharma and Cipla are forging a closer bonding. GlaxoSmithkline is believed to be in discussions to source inhlation devices from Cipla for Asia.

And though Cipla chose not to comment, Glaxo officials maintained that the news is speculative but the company works with partners keeping in mind specific local manufacturing advantages.

Analysts say the sourcing deal works well for both the companies. While GlaxoSmithkline has a clear dominance over the world market for respiratory products, Cipla has been making a steady headway in devices such as aerosols.

Interestingly, while Cipla ranks as the top drugmaker in the domestic market, GlaxoSmithkline ranks third with an almost similar product basket as that of Cipla.
 
The two companies compete in various segments including respiratory drugs, anti-infectives, anti-aids drugs and drugs for chronic diseases such as diabetes and vardiovascular ailments.
 
Cipla is known globally for its inhalation products manufactured at cheap costs and Glaxo's compulsions to cut costs for its own products may get the two rivals work closely.

Cipla is in preliminary talks with Reliance Retail for outsourcing the products.

When approached, Cipla refused to comment and Glaxo UK said the news is speculative.

Disclaimer: This information is source-based and has not been provided to the stock exchanges.

  

Trending News

Business News

Sony to roll-out ICS update next week, Xperia PLAY gets the boot
Reebok execs named in Rs 870 cr fraud denied anticipatory bail "Reebok execs named in Rs 870 cr fraud denied anticipatory bail"

Live Updates: KKR favourites in last-over battle

Rel Comm Q4 Cons Net Revenue Up 5% At `5,310 Cr (QoQ)

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 27 2012, 11:52 | Source: CNBC-TV18

Expect to maintain EBIDTA margin ahead: Wockhardt  

May 27 2012, 11:00 | Source: CNBC-TV18

e-commerce market in India: What's in store?  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!